BPG is committed to discovery and dissemination of knowledge
Retrospective Study
©The Author(s) 2025.
World J Gastrointest Oncol. Dec 15, 2025; 17(12): 113976
Published online Dec 15, 2025. doi: 10.4251/wjgo.v17.i12.113976
Table 4 Comparison of features between the training and validation sets, n (%)
Variables
Total (n = 300)
Validation (n = 90)
Training (n = 210)
Statistic
P value
Genderχ² = 0.220.639
Female89 (29.67)25 (27.78)64 (30.48)
Male211 (70.33)65 (72.22)146 (69.52)
Ageχ² = 0.770.381
< 50118 (39.33)32 (35.56)86 (40.95)
≥ 50182 (60.67)58 (64.44)124 (59.05)
BMIχ² = 0.260.614
< 25216 (72.00)63 (70.00)153 (72.86)
≥ 2584 (28.00)27 (30.00)57 (27.14)
Adjuvant therapyχ² = 1.130.288
No72 (24.00)18 (20.00)54 (25.71)
Yes228 (76.00)72 (80.00)156 (74.29)
T stageχ² = 1.520.678
T150 (16.67)14 (15.56)36 (17.14)
T249 (16.33)16 (17.78)33 (15.71)
T3129 (43.00)42 (46.67)87 (41.43)
T472 (24.00)18 (20.00)54 (25.71)
N stageχ² = 2.460.483
N0100 (33.33)28 (31.11)72 (34.29)
N154 (18.00)19 (21.11)35 (16.67)
N250 (16.67)18 (20.00)32 (15.24)
N396 (32.00)25 (27.78)71 (33.81)
LN metaχ² = 0.850.355
No105 (35.00)28 (31.11)77 (36.67)
Yes195 (65.00)62 (68.89)133 (63.33)
Vein invχ² = 0.210.646
No126 (42.00)36 (40.00)90 (42.86)
Yes174 (58.00)54 (60.00)120 (57.14)
Nerve invχ² = 1.030.309
No130 (43.33)43 (47.78)87 (41.43)
Yes170 (56.67)47 (52.22)123 (58.57)
CTIχ² = 0.110.741
< 9.07169 (56.33)52 (57.78)117 (55.71)
≥ 9.07131 (43.67)38 (42.22)93 (44.29)
PNIχ² = 0.250.616
< 4586 (28.67)24 (26.67)62 (29.52)
≥ 45214 (71.33)66 (73.33)148 (70.48)
CEAχ² = 0.580.446
< 3170 (56.67)54 (60.00)116 (55.24)
≥ 3130 (43.33)36 (40.00)94 (44.76)
CA199χ² = 2.240.135
< 37256 (85.33)81 (90.00)175 (83.33)
≥ 3744 (14.67)9 (10.00)35 (16.67)


Write to the Help Desk